BIVI BIOVIE INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1580149 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY54.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-143.7%
ROA-119.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets40.9%
Debt / equity0.00x
Current ratio2.40x
Interest coverage-1,363.57x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-19.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $13.96M | $9.27M |
| SG&A expense | $8.51M | $8.57M |
| Operating income | -$22.65M | -$18.07M |
| Interest expense | $17,901 | $332,720 |
| Net income | -$22.07M | -$17.54M |
| EPS (basic) | -3.05 | -12.12 |
| EPS (diluted) | -3.05 | -12.12 |
| Weighted avg. shares (diluted) | 7.25M | 1.48M |
| Balance sheet | ||
| Cash & equivalents | $8.98M | $17.54M |
| Current assets | $13.64M | $20.70M |
| Goodwill | $345,711 | $345,711 |
| Intangibles | — | $178,341 |
| Total assets | $14.25M | $21.56M |
| Current liabilities | $3.80M | $2.27M |
| Total liabilities | $3.98M | $2.55M |
| Shareholders' equity | $10.27M | $19.01M |
| Shares outstanding | 7.54M | 1.91M |
| Cash flow statement | ||
| Operating cash flow | -$19.02M | -$19.03M |
| Financing cash flow | $10.46M | $12.73M |
| Stock-based compensation | $2.28M | $1.20M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.